Publication at First Faculty of Medicine |
2011
Abstract
Data overview from randomized double-blind observation, placebo-controlled studies and from meta-analyses has shown that oral ibandronate administered as 150 mg once a month or as 3 mg iv once in three months represents effective, safe and well-tolerated therapy. Both these regimens use ACE more 10.8 mg and provide significant efficacy in terms of reduced risk of clinical and non-vertebral fractures.
Data from MOBILE and DIVA LTE trials have confirmed lasting efficacy of both these regimens of ibandronate administration for five years. Better patient adherence to therapy is associated with higher efficacy and protection from fractures, and holds promise for reducing future economic costs related to osteoporosis as well.